000			02906cam a2200337 a 4500
003			EG-GiCUC
005			20250223031702.0
008			170314s2016 ua h f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.08.08.Ph.D.2016.Ma.A
100	0		_aMayssa Abdelhady Mohamed
245	1	0	_aApplication of nanotechnology for ocular drug delivery / _cMayssa Abdelhady Mohamed ; Supervised Mahmoud M. Ghorab , Hamed A. Salama
246	1	5	_aإستخدإم التقنية النانومرتية لتوصيل الدواء للعين
260			_aCairo : _bMayssa Abdelhady Mohamed , _c2016
300			_a150 P. : _bfacsimiles ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520			_aBrinzolamide, a carbonic anhaydrase inhibitor, is commercially formulated as a 1% ophthalmic suspension to reduce intraocular pressure (IOP). The commercially available preparation of brinzolamide is Azopt® (Alcon Laboratories, Inc, Ft. Worth, Texas, USA). The most common ocular adverse events on using brinzolamide eye drops are blurred vision (3-8%), ocular discomfort (1.8-5.9%) and eye pain (0.7-4.0%). Other ocular adverse events occurring at an incidence of less than 3% include hyperemia, pruritus, tearing, discharge, blepharitis, keratitis, foreign body sensation, dry eye, conjunctivitis and lid margin crusting. Antiglaucoma agents may be administered topically or systemically for the treatment of elevated IOP. Topical application of drugs has remained the most preferred method due to ease of administration and low cost. Anatomical and physiological barriers hinder drugs from reaching posterior segment of the eye, mainly at choroid and retina. A major fraction of drug following topical administration is lost by lacrimation, tear dilution, nasolacrimal drainage and tear turnover. Such precorneal losses result in very low ocular bioavailability. Typically, less than 5% of the total administrated dose reaches aqueous humor. Therefore, in order to maintain minimum effective concentrations, the agents need to be frequently dosed resulting in poor patient compliance. Topical medications have been also noted to induce long term ocular surface changes which may often cause damage to conjunctival and corneal cells. The deleterious effects of preservatives on the ocular surface are of particular concern for patients with chronic conditions such as glaucoma or keratoconjunctivitis sicca
530			_aIssued also as CD
653		4	_aBrinzolamide
653		4	_aNanotechnology
653		4	_aPharmaceutics
700	0		_aHamed Abdelaziz Salama , _eSupervisor
700	0		_aMahmoud Mohamed Ghorab , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c60242 _d60242